ADHD

Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...

Ann Childress , MD;

10/26/2023

Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.

Andrew J. Cutler , MD;

10/26/2023

Growth Trajectories of Youth with Attention-Deficit/Hyperactivity Disorder Treated with Delayed-Release/Extended-Release Methylphenidate: A Pilot Database Analysis of Real-World Data

DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...

Karl Weddige , PhD;

10/26/2023

Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study

Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...

Jessica McDonough , MD;

10/26/2023

52-Week Open-Label Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...

Jessica McDonough , MD;

10/26/2023

A Phase 3, safety and efficacy, adult laboratory classroom study in subjects with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (dexmethylphenidate).

Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...

Ann Childress , MD;

10/26/2023

A Randomized, Five-Way Crossover Study to Evaluate Bioequivalence of the Dextroamphetamine Transdermal System (d-ATS) at Five Application Sites in Healthy Adults

In a pivotal study, d-ATS applied to the hip met primary and secondary efficacy endpoints for ADHD in children and adolescents. In this open-label crossover study, healthy adults were ran...

Mahwish Khan , PharmD, RPh;

10/26/2023

A Thorough QT Trial Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization

Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...

Osman Turkoglu , MD;

10/26/2023

Videos

Understanding the Stimulant Shortage

09/05/2023

Greg Mattingly, MD

Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.

Dr Mattingly explains the...

09/05/2023

Psych Congress Network

Viloxazine Extended-Release Capsules (Qelbree®) for Adults with Attention-Deficit/Hyperactivity Disorder: Evaluating the Potential Impact of Caffeine Exposure on Safety Profile

Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...

Jami Earnest ;

Azmi Nasser , PhD;

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia-Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.